Oligodendrocyte precursor cell (OPC) therapy is a cell-based approach for treating demyelinating diseases and promoting remyelination in neurodegenerative conditions. OPCs are glial progenitor cells that differentiate into oligodendrocytes, the myelin-producing cells of the central nervous system (CNS). This therapy aims to transplant OPCs or stimulate endogenous OPCs to regenerate myelin sheaths damaged in conditions like multiple sclerosis (MS), Alzheimer's disease (AD), and Parkinson's disease (PD). [1]
Oligodendrocytes produce the myelin sheath that insulates axons, enabling rapid saltatory conduction. OPCs comprise approximately 5-10% of cells in the adult human brain and remain proliferative and responsive to demyelination. [2]
Direct Remyelination: Transplanted or endogenous OPCs differentiate into mature oligodendrocytes that wrap axons with new myelin.
Neurotrophic Support: OPCs secrete growth factors (NGF, BDNF, GDNF) that support neuron survival.
Immunomodulation: OPCs can modulate inflammatory responses in the CNS.
Axonal Support: Myelination provides metabolic support to axons through lactate shuttling.
| Cell Type | Source | Advantages | Challenges | [3]
|-----------|--------|------------|------------| [4]
| Human OPCs | Fetal brain tissue | Native myelinating cells | Limited supply; ethical concerns | [5]
| iPSC-derived OPCs | Patient iPSCs | Unlimited supply; patient-matched | Functional maturity | [6]
| MSC-derived OPCs | Bone marrow | Accessible; immunomodulatory | Myelination efficiency | [7]
| NG2 glia | Adult CNS | Endogenous repair capacity | Isolation challenges | [8]
| Trial | Cell Type | Phase | Key Findings | [9]
|-------|-----------|-------|--------------| [10]
| NCT03269071 | Autologous MSCs | Phase 1/2 | Safety; some MRI improvements |
| NCT03799744 | Umbilical cord OPCs | Phase 1 | Ongoing |
| NCT05030116 | iPSC-derived OPCs | Phase 1 | Recruiting |
| Trial | Approach | Phase | Rationale |
|---|---|---|---|
| NCT05838438 | OPC transplantation | Preclinical | White matter repair |
| NCT04624217 | OPC-secreted factors | Phase 1 | Neurotrophic support |
Zhang et al. Human OPC transplantation in demyelinating disease (2006). 2006. ↩︎
Sim et al. Direct conversion of fibroblasts to OPCs (2011). 2011. ↩︎
Najm et al. Drug discovery for remyelination (2015). 2015. ↩︎
Cao et al. OPC therapy for AD in mouse models (2019). 2019. ↩︎
Windrem et al. Neonatal human OPCs for myelination (2008). 2008. ↩︎
Bergles & Richardson, Oligodendrocyte precursor cells in disease (2015). 2015. ↩︎
Patani et al. OPC biology and therapy (2021). 2021. ↩︎
Kremer et al. Remyelination strategies (2021). 2021. ↩︎